Kumar Kartik, Gill Anna, Shafei Rachelle, Wright Janine L
North Middlesex University Hospital NHS Trust, London, UK.
BMJ Case Rep. 2014 Dec 5;2014:bcr2014205331. doi: 10.1136/bcr-2014-205331.
Terbinafine is a commonly prescribed antifungal agent used in the treatment of trichophytic onychomycosis and chronic cutaneous mycosis that are resistant to other treatments. This case report highlights a rarely documented but important adverse hepatic reaction that was caused by the use of oral terbinafine. A woman in her thirties presented with a 3-week history of jaundice, malaise, itching, nausea, decreased appetite, weight loss, dark orange urine and intermittent non-radiating epigastric pain. She had recently finished a 3-week course of oral terbinafine for a fungal nail infection. Liver biopsy findings were consistent with chronic active hepatitis secondary to a drug reaction. A few days after initial presentation, the patient developed erythema nodosum. Delayed development of erythema nodosum secondary to terbinafine could not be excluded.
特比萘芬是一种常用的抗真菌药物,用于治疗对其他治疗有抗性的毛癣菌性甲癣和慢性皮肤真菌病。本病例报告强调了一种由口服特比萘芬引起的虽罕见但重要的肝脏不良反应。一名三十多岁的女性出现黄疸、不适、瘙痒、恶心、食欲减退、体重减轻、深橙色尿液和间歇性非放射性上腹部疼痛3周。她最近因真菌性指甲感染完成了一个为期3周的口服特比萘芬疗程。肝活检结果与药物反应继发的慢性活动性肝炎一致。初次就诊几天后,患者出现结节性红斑。不能排除特比萘芬继发结节性红斑的延迟发生。